Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2002; 23(6): 589-596
DOI: 10.1055/s-2002-36522
DOI: 10.1055/s-2002-36522
Therapy for Extrapulmonary Sarcoidosis
Further Information
Publication History
Publication Date:
07 January 2003 (online)
ABSTRACT
The treatment of extrapulmonary sarcoidosis has to be adapted to the various organs involved. No treatment is necessary for most asymptomatic individuals. In some cases, topical therapy is sufficient to control problems, especially skin and eye involvement. Systemic therapy usually starts with corticosteroids. However, for chronic forms of the disease, steroid sparing alternatives such as methotrexate and hydroxychloroquine are useful. In some neurologic and cardiac cases, the response to corticosteroids is limited. In that case, alternatives are sought for these refractory patients. Drugs that inhibit tumor necrosis factor may prove useful in these patients. Among the new anti-tumor necrosis factor drugs are thalidomide and infliximab, an antibody to tumor necrosis factor.
KEYWORD
Methotrexate - hydroxychloroquine - azathioprine - infliximab - thalidomide - tumor necrosis factor - prednisone
REFERENCES
- 1 Hunninghake G W, Costabel U, Ando M. ATS/ERS/ WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis . 1999; 16 149-173
- 2 Baughman R P, Lower E E. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis . 1997; 14 121-130
- 3 Zeitlin J F, Tami T A, Baughman R, Winget D. Nasal and sinus manifestations of sarcoidosis. Am J Rhinol . 2000; 14 157-161
- 4 Lower E E, Broderick J P, Brott T G, Baughman R P. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med . 1997; 157 1864-1868
- 5 Mana J, Gomez Vaquero C, Montero A. Lofgren's syndrome revisited: a study of 186 patients. Am J Med . 1999; 107 240-245
- 6 James D G, Sharma O P. Parotid gland sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis . 2000; 17 27-32
- 7 Engasser P G, Maibach H I. Cosmetic and dermatology: bleaching creams. J Am Acad Dermatol . 1981; 5 143-147
- 8 Controlled evaluation of loteprendnol etabonate and prednisolone acetate in the treatment of acute anterior uveitis: loteprednol etabonate US uveitis study. Am J Ophthalmol . 1999; 127 597-599
- 9 Francois J, Victoria-Troncoso V. Corticosteroid glaucoma. Ophthalmologica . 1977; 174 195-209
- 10 Jonas J B, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol . 2001; 132 425-427
- 11 Gelwan M J, Kellen R I, Burde R M, Kupersmith M J. Sarcoidosis of the anterior visual pathway: successes and failures. J Neurol Neurosurg Psychiatry . 1988; 51 1473-1480
- 12 Agbogu B N, Stern B J, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol . 1995; 52 875-879
- 13 Hunninghake G W, Gilbert S, Pueringer R. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med . 1994; 149 893-898
- 14 Gottlieb J E, Israel H L, Steiner R M, Triolo J, Patrick H. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest . 1997; 111 623-631
- 15 Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis . 1998; 15 52-58
- 16 Baughman R P, Shipley R, Eisentrout C E. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung . 1987; 165 371-377
- 17 Neville E, Walker A N, James D G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med . 1983; 208 525-533
- 18 Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax . 1995; 50 555-559
- 19 Siltzbach L E, Teirstein A S. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand . 1964; 425(suppl) 302S-308S
- 20 Jones E, Cagen J P. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. Am Acad Dermatol . 1990; 23 487-490
- 21 Henderson C A, Ilchyshyn A, Curry A R. Laryngeal and cutaneous sarcoidosis treated with methotrexate. J R Soc Med . 1994; 87 632-633
- 22 Rajendran R, Theertham M, Salgia R, Muthuswamy P. Methotrexate in the treatment of cutaneous sarcoidosis. Sarcoidosis . 1994; 11(suppl) S335-S338
- 23 Veien N K, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol . 1977; 97 213-216
- 24 Webster G F, Razsi L K, Sanchez M, Shupack J L. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol . 1991; 24 451-454
- 25 Lower E E, Baughman R P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med . 1995; 155 846-851
- 26 Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol . 1995; 32 866-869
- 27 Lee J B, Koblenzer P S. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol . 1998; 39 835-838
- 28 Krzystolik M, Power W J, Foster C S. Diagnostic and therapeutic challenges of sarcoidosis. International Ophthalmology Clinics . 1998; 38 61-76
- 29 Van Gelder N R, Kaplan H J. Immunosuppression in uveitis therapy. Springer Seminars in Immunopathology . 1999; 21 179-190
- 30 Dev S, McCallum R M, Jaffe G J. Methotrexate for sarcoid-associated panuveitis. Opthalmology . 1999; 106 111-118
- 31 Baughman R P, Lower E E, Bradley D A, Kaufman A H. Use of cytotoxic therapy for chronic opthalmic sarcoidosis. Sarcoidosis Vasc Diff Lung Dis . 1999; 16(suppl) S17
- 32 Samson C M, Waheed N, Baltatzis S, Foster C S. Methotrexate therapy for chronic nonifectious uveitis: analysis of a case series of 160 patients. Ophthalmology . 2001; 108 1134-1139
- 33 Gedalia A, Molina J F, Ellis G S, Galen W, Moore C, Espinoza L R. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr . 1997; 130 25-29
- 34 Lennarson P, Barney N P. Interstitial keratitis as presenting ophthalmic sign of sarcoidosis in a child. J Pediatr Ophthalmol Strabismus . 1996; 32 194-196
- 35 Shetty A K, Zganjar B E, Ellis Jr S G, Ludwig I H, Gedalia A. Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus . 1999; 36 125-128
- 36 Kaye O, Palazzo E, Grossin M, Bourgeois P, Kahn M F, Malaise M G. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol . 1995; 34 642-644
- 37 Rizzato G, Montemurro L, James D G. Sarcoidosis and other granulomatous disorders.
New York: Marcel Dekker 1994
MissingFormLabel
- 38 James D G, Carstairs L S, Trowell J, Sharma O P. Treatment of sarcoidosis: report of a controlled therapeutic trial. Lancet . 1967; 2 526-528
- 39 Oksanen V. Neurosarcoidosis: clinical presentations and course in 50 patients. Acta Neurol Scand . 1986; 73 283-290
- 40 Sharma O P. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest . 1997; 112 220-228
- 41 James D G. Differential diagnosis of facial nerve palsy. Sarcoidosis . 1997; 14 115-120
- 42 Hunninghake G W, Costabel U, Ando M. ATS/ERS/ WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis . 1999; 16 149-173
- 43 O'Brien G M, Baughman R P, Broderick J P, Arnold L, Lower E E. Paranoid psychosis due to neurosarcoidosis. Sarcoidosis . 1994; 11 34-36
- 44 Sharma O P. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurologic involvement. Arch Neurol . 1998; 55 1248-1254
- 45 Martinet Y, Pinkston P, Saltini C, Spurzem J, Muller-Quernheim J, Crystal R G. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis . 1996; 138 1242-1248
- 46 Wyser C P, van Schalkwyk M E, Alheit B, Bardin P G, Joubert J R. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med . 1997; 156 1571-1576
- 47 Stern B J, Schonfeld S A, Sewell C, Krumholz A, Scott P, Belendiuk G. The treatment of neurosarcoidosis with cyclosporine. Arch Neurol . 1992; 49 1065-1072
- 48 Zuber M, Defer G, Cesaro P, Degos J D. Efficacy of cyclophosphamide in sarcoid radiculomyelitis. J Neurol Neurosurg Psychiatry . 1992; 55 166-167
- 49 Bullmann C, Faust M, Hoffmann A. Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis. Eur J Endocrinol . 2000; 142 365-372
- 50 Zajicek J P, Scolding N J, Foster O. Central nervous system sarcoidosis: diagnosis and management. QJM . 1999; 92 103-117
- 51 Kang S, Suh J H. Radiation therapy for neurosarcoidosis: report of three cases from a single institution. Radiation Oncol Invest . 1999; 7 309-312
- 52 Yoshida T, Tanaka M, Okamoto K, Hirai S. Neurosarcoidosis following augmentation mammoplasty with silicone. Neurol Res . 1996; 18 319-320
- 53 Nakagawa K, Tago M, Terahara A. A single institutional outcome analysis of Gamma Knife radiosurgery for single or multiple brain metastases. Clin Neurol Neurosurg . 2000; 102 227-232
- 54 Vigliani M C, Duyckaerts C, Hauw J J, Poisson M, Magdelenat H, Delattre J Y. Dementia following treatment of brain tumors with radiotherapy administered alone or in combination with nitrosourea-based chemotherapy: a clinical and pathological study. J Neuro-oncol . 1999; 41 137-149
- 55 Baughman R P, Winget D B, Bowen E H, Lower E E. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis . 1997; 14 154-158
- 56 Suzuki T, Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest . 1994; 106 1021-1024
- 57 Paz H L, McCormick D J, Kutalek S P, Patchefsky A. The automated implantable cardiac defibrillator: prophylaxis in cardiac sarcoidosis. Chest . 1994; 106 1603-1607
- 58 DeRemee R A. The present status of therapy of pulmonary sarcoidosis: a house divided. Chest . 1977; 71 388-393
- 59 Rizzato G, Fraioli P, Montemurro L. Long-term therapy with deflazacort in chronic sarcoidosis. Chest . 1991; 99 301-309
- 60 Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int . 1991; 49 71-76
- 61 Gonnelli S, Rottoli P, Cepollaro C. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int . 1997; 61 382-385
- 62 Rizzato G, Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. Eur Respir J . 1993; 6 116-119
- 63 Lacher M J. Spontaneous remission response to methotrexate in sarcoidosis. Ann Intern Med . 1968; 69 1247-1248
- 64 Lower E E, Baughman R P. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci . 1990; 299 153-157
- 65 Baughman R P, Lower E E. A clinical approach to the use of methotrexate for sarcoidosis. Thorax . 1999; 54 742-746
- 66 Morgan S L, Baggott J E, Vaughn W H. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med . 1994; 121 833-841
- 67 Baughman R P, Winget D B, Lower E E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis . 2000; 17 60-66
- 68 Fries J F, Ramey D R, Singh G. Suggested guidelines for monitoring liver toxicity in rheumatoid arthritis patients with methotrexate: comment on the article by Kremer et al. Arthritis Rheum . 1994; 37 1829-1830
- 69 Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy: conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis . 1996; 55 273-275
- 70 Kremer J M, Alarcon G S, Lightfoot Jr W R. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum . 1994; 37 316-328
- 71 Baughman R P, Weber F L, Bejarano P B, Koehler A, Lower E E. Methotrexate for chronic sarcoidosis: hepatotoxicity assessed by liver biopsy. Am J Respir Crit Care Med . 1999; 159 A342
- 72 White D A, Rankin J A, Stover D E, Gellene R A, Gupta S. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis . 1989; 139 18-21
- 73 Grierson D J. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis . 1997; 56 188-190
- 74 Jones S K. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol . 1999; 140 3-7
- 75 Mazzuca S A, Yung R, Brandt K D, Yee R D, Katz B P. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol . 1994; 21 59-63
- 76 Ben Ari Z, Mehta A, Lennard L, Burroughs A K. Azathioprine-induced myelosuppression due to methyltransferase defiency in a patient with autoimmune hepatitis. J Hepatology . 1995; 23 351-354
- 77 Escousse A, Mousson C, Santona L. Azathioprine-induced pancytopenia in homogenous thioprine methyltransferase-deficient renal transplant recipeints: a family study. Transplant Proc . 1995; 27 1739-1742
- 78 Fries J F, Williams C A, Ramey D, Bloch D A. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum . 1993; 36 297-306
- 79 Ritters B, Grabensee B, Heering P. Malignancy under immunosuppressive therapy including cyclosporin. Transplant Proc . 1994; 26 2656-2657
- 80 Taylor A E, Shuster S. Skin cancer after renal transplant: the causal role of azathioprine. Acta Dermatology and Venereology . 1992; 72 115-119
- 81 McGeown M G, Douglas J F, Middleton D. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. Clin Transpl . 2000; 16 193-202
- 82 Singh G, Fries J F, Williams C A, Zatarain E, Spitz P, Bloch D A. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol . 1991; 18 188-194
- 83 Lamers C B, Griffioen G, Van Hogezand A R, Veenendaal R A. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol . 1999; 230(suppl) 111-115
- 84 Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology . 1996; 46 1607-1612
- 85 Zisman D A, Lynch J P, Toews G B, Kazerooni E A, Flint A, Martinez F J. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest . 2000; 117 1619-1626
- 86 Baughman R P, Lower E E. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest . 1992; 102 1090-1094
- 87 Talar-Williams C, Hijazi Y M, Walther M M. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med . 1996; 124 477-484
- 88 Schoenike S E. Ifosfamide and mesna. Clin Pharmacol . 1990; 9 179-191
- 89 Lower E E, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med . 1999; 8 949-954
- 90 Strieter R M, Remick D G, Ward P A. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun . 1988; 155 1230-1236
- 91 Marques L J, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med . 1999; 159 508-511
- 92 Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med . 1997; 155 1665-1669
- 93 Sheskin J. Thalidomide in the treatment of lepra reaction. Clin Pharmacol Ther . 1965; 6 303
- 94 Jacobson J M, Greenspan J S, Spritzler J. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med . 1997; 336 1487-1493
- 95 Singhal S, Mehta J, Desikan R. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med . 1999; 341 1565-1571
- 96 Rousseau L, Beylot-Barry M, Doutre M S, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol . 1998; 134 1045-1046
- 97 Baughman R P, Judson M A, Teirstein A S, Moller D R, Lower E E. Thalidomide for chronic sarcoidosis. Chest . 2002; 122 227-232
- 98 Marriott J B, Cookson S, Carlin E. A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: clinical tolerance and effect on activation markers and cytokines. AIDS Res Human Retroviruses . 1997; 13 1625-1631
- 99 Gerr F E, Letz R. Reliability of a widely used test of peripheral cutaneous vibration sensitivity and a comparison of two testing protocols. Brit J Industrial Med . 1988; 45 635-639
- 100 Hamuryudan V, Mat C, Saip S. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. Ann Intern Med . 1998; 128 443-450
- 101 Kavanaugh A, Clair E W, McCune W J, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol . 2000; 27 841-850
- 102 Maini R, St Clair W E, Breedveld F. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet . 1999; 354 1932-1939
- 103 Lofberg R. Treatment of fistulas in Crohn's disease with infliximab. Gut . 1999; 45 642-643
- 104 Chaudhari U, Romano P, Mulcahy L D, Dooley L T, Baker D G, Gottlieb A B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet . 2001; 357 1842-1847
- 105 Oh C J, Das K M, Gottlieb A B. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol . 2000; 42 829-830
- 106 Sfikakis P P, Theodossiadis P G, Katsiari C G, Kaklamanis P, Markomichelakis N N. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet . 2001; 358 295-296
- 107 Baughman R P, Lower E E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis . 2001; 18 70-74
- 108 Yee A MF, Pochapin M B. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis-alpha therapy. Ann Intern Med . 2001; 135 27-31
- 109 Alabi O F, Lower E E, Baughman R P. Use of infliximab in refractory sarcoidosis. Am J Respir Crit Care Med . 2001; 163 A557
- 110 Schaible T F. Long term safety of infliximab. Can J Gastroenterol . 2000; 14 (suppl C) 29C-32C
- 111 Charles P J, Smeenk R J, De Jong J, Feldmann M, Maini R N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis and Rheumatism . 2000; 43 2383-2390
- 112 Kean J, Gershon S, Wise R P. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med . 2001; 345 1098-1104